Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

erzotabart

A hexamerization-enhanced human immunoglobulin G1 (IgG1) monoclonal antibody that targets the cell surface glycoprotein CD-38 and carries the E430G mutation, with potential immunomodulating and antineoplastic activities. Upon administration, erzotabart targets and binds to CD38 on CD38-positive tumor cells, thereby forming antibody hexamers through increased intermolecular Fc-Fc interactions upon antigen binding. This may trigger direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by GEN3014 induces downmodulation of CD38, inhibits CD38 cyclase activity, and may abrogate immune suppression in the tumor microenvironment (TME). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD38 monoclonal antibody GEN3014
HexaBody-CD38
Code name:GEN 3014
GEN-3014
GEN3014
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search